Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02657369 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
A Phase 2 study, sponsored by Eisai.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02657369 is a Phase 2 study that was terminated before completion, run by Eisai. The registered enrollment target is 34 participants.
The verdict
NCT02657369, a Phase 2 study, was terminated before completion, sponsored by Eisai.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate objective response rate (\[ORR\]: complete response \[CR\] and partial response \[PR\]) by investigator review in participants with anaplastic thyroid cancer (ATC) treated with lenvatinib.
Interventions
- DRUG Lenvatinib 24 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-07-07 |
| Est. Completion | 2018-09-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02657369
The ClinicalTrials.gov registry entry for NCT02657369 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenvatinib 24 mg is the first listed.
NCT02657369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02657369 about?
NCT02657369 is a clinical study titled "A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)". The primary purpose of the study is to evaluate objective response rate (\[ORR\]: complete response \[CR\] and partial response \[PR\]) by investigator review in participants with anaplastic thyroid cancer (ATC) treated with lenvatinib.
What is the current status of trial NCT02657369?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2016-07-07. Estimated completion is 2018-09-26.
What interventions are being tested in trial NCT02657369?
The interventions under investigation include: Lenvatinib 24 mg (DRUG).
Who is sponsoring clinical trial NCT02657369?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.